BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) insider Lai Wang sold 1,177 shares of the company’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $266.40, for a total transaction of $313,552.80. Following the transaction, the insider now owns 470 shares of the company’s stock, valued at approximately $125,208. This represents a 71.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Lai Wang also recently made the following trade(s):
- On Tuesday, June 17th, Lai Wang sold 470 shares of BeOne Medicines stock. The stock was sold at an average price of $251.37, for a total transaction of $118,143.90.
- On Friday, June 6th, Lai Wang sold 1,402 shares of BeOne Medicines stock. The stock was sold at an average price of $252.39, for a total transaction of $353,850.78.
BeOne Medicines Stock Performance
NASDAQ:ONC opened at $252.78 on Friday. The firm has a market cap of $27.69 billion, a P/E ratio of -67.95 and a beta of 0.30. The firm’s 50 day moving average price is $245.25. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.71. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $141.31 and a fifty-two week high of $287.88.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the stock. TD Securities reiterated a “buy” rating and set a $334.00 price target on shares of BeOne Medicines in a report on Thursday, April 24th. Bank of America raised BeOne Medicines from a “neutral” rating to a “buy” rating and upped their target price for the stock from $207.00 to $320.00 in a report on Monday, March 3rd. JMP Securities set a $348.00 price objective on BeOne Medicines in a research note on Friday, February 28th. Macquarie upped their price target on shares of BeOne Medicines from $259.00 to $313.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. Finally, JPMorgan Chase & Co. increased their price objective on BeOne Medicines from $311.00 to $317.00 and gave the company an “overweight” rating in a report on Monday, April 21st. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, BeOne Medicines currently has an average rating of “Buy” and a consensus price target of $319.00.
Read Our Latest Report on BeOne Medicines
BeOne Medicines Company Profile
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Featured Stories
- Five stocks we like better than BeOne Medicines
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Robinhood Director Sells Millions, But HOOD Stock Eyes Gains
- Compound Interest and Why It Matters When Investing
- Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill
- Upcoming IPO Stock Lockup Period, Explained
- Super Micro Computer Stock’s Rally Backed by Strong Financials
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.